Chemotherapy for advanced breast cancer - How long should it continue?

Breast Cancer Research and Treatment

Volumn 81, Issue SUPPL. 1, 2003, Pages

  Stockler, Martin R ^a,b,c   Wilcken, Nicholas J C ^a,d   Coates, Alan S ^a,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e CANCER COUNCIL AUSTRALIA   (Australia)

Author keywords

Advanced breast cancer; Chemotherapy; Duration; Meta analysis; Randomised clinical trials

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; TAMOXIFEN; VINCRISTINE;

ANOREXIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; FATIGUE; HUMAN; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0345304840     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026316806601     Document Type: Conference Paper

References (11)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998
2. Stockler M, Wilcken N: The management of advanced breast cancer: systematic reviews of randomised controlled trials regarding the use of cytotoxic chemotherapy and endocrine therapy. For the Advanced Breast Cancer Working Party of the NHMRC National Breast Cancer Centre.
3. Stockler M, Wilcken N, Ghersi D, Simes RJ: Systematic reviews of systemic therapy for advanced breast cancer. Cancer Treatment Rev 26: 151-168, 2000
4. Stockler M, Wilcken N, Coates A: Chemotherapy for metastatic breast cancer - when is enough? Eur J Cancer 33: 2147-2148, 1997
5. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R et al.: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490-1495, 1987
6. Coates A, Byrne M, Bishop JF, Forbes JF: Intermittent versus continuous chemotherapy for breast cancer. N Engl J Med 318: 1468, 1988
7. Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P et al.: Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335: 186-190, 1990
8. Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen HT, Rose C, Overgaard et al.: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A: 527-531, 1993
9. Gregory RK, Powles TJ, Chang J, Ashley S: A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33: 2194-2197, 1997
10. Duric V, Stockler M: A systematic review of studies assessing patients' preferences for adjuvant chemotherapy in early breast cancer: What makes it worthwhile? Lancet Oncol 2: 691-697, 2001
11. Slevin ML, Stubbs L, Plant HJ et al.: Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300: 1458-1460, 1990